165 related articles for article (PubMed ID: 36738309)
1. The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer.
Yang L; Zhang W; Sun J; Yang G; Cai S; Sun F; Xing L; Sun X
Cancer Immunol Immunother; 2023 Jul; 72(7):2015-2027. PubMed ID: 36738309
[TBL] [Abstract][Full Text] [Related]
2. Functional status and spatial interaction of T cell subsets driven by specific tumor microenvironment correlate with recurrence of non-small cell lung cancer.
Yang L; Zhang W; Sun J; Yang G; Cai S; Sun F; Xing L; Sun X
Front Immunol; 2022; 13():1022638. PubMed ID: 36685566
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
5. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
6. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
7. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR
Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778
[TBL] [Abstract][Full Text] [Related]
8. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
Wu F; Jiang T; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Bai X; Ren S; Zhou C;
Cancer Commun (Lond); 2022 Dec; 42(12):1331-1346. PubMed ID: 36331328
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
11. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract][Full Text] [Related]
12. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
[TBL] [Abstract][Full Text] [Related]
13. Functional status and spatial architecture of tumor-infiltrating CD8+ T cells are associated with lymph node metastases in non-small cell lung cancer.
Yang G; Cai S; Hu M; Li C; Yang L; Zhang W; Sun J; Sun F; Xing L; Sun X
J Transl Med; 2023 May; 21(1):320. PubMed ID: 37173705
[TBL] [Abstract][Full Text] [Related]
14. Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients.
Yang Y; Yang X; Wang Y; Xu J; Shen H; Gou H; Qin X; Jiang G
Front Immunol; 2022; 13():811007. PubMed ID: 35222387
[TBL] [Abstract][Full Text] [Related]
15. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
16. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Cancer Immunol Immunother; 2021 Apr; 70(4):1063-1074. PubMed ID: 33113005
[TBL] [Abstract][Full Text] [Related]
17. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8
Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G
Front Immunol; 2021; 12():680973. PubMed ID: 34122444
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
19. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
Xing YF; Pan X; Qian B; Shi MH
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748
[No Abstract] [Full Text] [Related]
20. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
